AI주식인사이트AI Stock Insight
C

오가노이드사이언스

476040KOSDAQ자연과학 및 공학 연구개발업

48.8 / 100

Reference Date: 2026-06-10

Financial Score14.5 / 40
News Sentiment21.3 / 25
Momentum3.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is undervalued vs. peers but the high debt ratio poses financial risk. Plunged 44.0% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Organoid Science is a biotech company developing regenerative therapies and material evaluation solutions based on organoid technology, including the refractory intestinal ulcer treatment ATORM-C and the ODISEI platform. The company is expanding into precision medicine, customized research reagents, and CDMO services, leveraging its advanced technology recognized as a national strategic innovation in 2023.

Number of Employees

89people

Average Salary

53.9M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 62.704.0Point
PBR
3.01Industry Average 3.244.0Point

In line with industry avg

ROE
-78.43Industry Average -32.093.5Point

2.4x industry avg (excellent)

Debt Ratio
19.43Industry Average 7.310.0Point

2.7x industry avg (risky)

Trend 3.0 / 10 points
Revenue Growth Rate
1.5 / 3

Operating Profit Growth Rate
1.5 / 3

ROE Trend
0.0 / 4

Detailed News Sentiment

8 totalPositive 8Neutral 0Negative 0Average Sentiment Score 85

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 11,360Won52-week high 44,60052-week low 11,360
1-month return0.0Point

1m -44.04% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0
  • Neutral투자판단관련주요경영사항 (오가노이드 기반 재생치료제 및 약물 스크리닝 플랫폼 관련 기술도입 계약 체결)2026-06-02
  • Neutral분기보고서 (2026.03)2026-05-15